"The company's Gagillapur facility located in Hyderabad, Telangana... Has successfully completed US FDA inspection without any observations," Granules India said in a BSE filing.
"This facility manufactures finished dosages (FDs) and pharmaceutical formulation intermediates (PFIs)."
The stock of Granules India was trading 2.29 per cent higher at Rs 122.75 on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content